Article info
PDFResearch ethics
Paper
Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?
- Correspondence to Dr Scott YH Kim, Department of Bioethics, National Institutes of Health, Clinical Center, 10 Center Drive, 1C118, Bethesda, MD 20892, USA, scott.kim{at}nih.gov, scottkim{at}med.umich.edu
Citation
Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?
Publication history
- Received December 17, 2015
- Revised February 8, 2016
- Accepted February 17, 2016
- First published March 10, 2016.
Online issue publication
November 03, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Understanding the ‘therapeutic misconception’ from the research participant’s perspective
- How not to test the prevalence of therapeutic misconception
- Pathophysiological insights into ALS with C9ORF72 expansions
- Sensitivity of brain MRI and neurological examination for detection of upper motor neurone degeneration in amyotrophic lateral sclerosis
- Absence of consensus in diagnostic criteria for familial neurodegenerative diseases
- Amyotrophic lateral sclerosis and motor neuron syndromes in Asia
- Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
- Parkinson's disease beyond 20 years
- Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?
- The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey